Eli Lilly and Company has chosen the Lehigh Valley in Pennsylvania for its next manufacturing site. With Lilly investing more than $3.5 billion in the site, the facility will produce next-generation weight-loss therapies. These include retatrutide, an investigational gastric inhibitory peptide (GIP), glucagon-like peptide-1 (GLP-1), and glucagon triple hormone receptor agonist. Lilly Increasing U.S. Manufacturing Pennsylvania is now the fourth U.S. location Lilly has announced plans for...